Exagen to Present at the Canaccord Genuity 40th Annual Growth Conference
July 30 2020 - 4:25PM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, today announced that Ron Rocca, President and
Chief Executive Officer of Exagen, will present at the Canaccord
Genuity 40th Annual Growth Conference on Wednesday, August 12,
2020, at 2:00 pm EDT. The conference will be a virtual event this
year.
Interested parties may access a link to the webcast of Mr.
Rocca’s presentation online from the investor relations section of
the Exagen website at https://investors.exagen.com/. A replay of
the webcast will be available using the link for 60 days after the
presentation.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on its proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis.
CONTACTS:
InvestorsWestwicke Partners Mike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838 Company
ContactExagen Inc. Kamal Adawi, Chief Financial
OfficerKAdawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024